Barclays Maintains DexCom Overweight, Raises Price Target to $120
Barclays maintained its Overweight rating on DexCom and raised its price target to $120 from $115.
Related stories
Global market picture: S&P 500 -0.29%, Nasdaq 100 -0.38%; EUR/USD -0.28%, WTI +0.41%
Global market picture. US index futures: S and P futures is down 0.29 percent, Nasdaq futures is down 0.38 percent, Dow futures is down 0.14 percent and Russell futures is down 0.2
M impact | EQUITY | Nov 15, 2026, 11:01 PM UTC
ULA Vulcan Rocket Fails, Destroying Payload of 40 Amazon Satellites
United Launch Alliance’s Vulcan rocket failed shortly after launching from Florida on Sunday, destroying 40 satellites for Amazon’s Leo internet network.
M impact | EQUITY | Nov 15, 2026, 08:46 PM UTC
Rocket Failure Destroys Payload of Amazon Satellites
A rocket from a Boeing-Lockheed venture failed mid-flight and destroyed its payload of Amazon satellites.
M impact | EQUITY | Nov 15, 2026, 08:46 PM UTC
ULA Vulcan Rocket Fails After Launch, 40 Amazon Satellites Doomed
A United Launch Alliance Vulcan rocket failed shortly after launch, dooming 40 Amazon low-Earth-orbit internet satellites.
M impact | EQUITY | Nov 15, 2026, 08:15 PM UTC
Serko Raises Annual Revenue Guidance as Business Travel Remains Robust
Serko reported first-half revenue of NZ$72.3 million, up 17% year on year, and a net loss of NZ$870,000. It said it will not pay an interim dividend and had NZ$63 million in cash a
M impact | EQUITY | Nov 15, 2026, 08:08 PM UTC
Nebius Reports Q3 Results, Narrows 2026 Revenue Guidance
Nebius said Q3 2026 results surpassed market estimates. Shares fell 17% as management narrowed its 2026 revenue outlook, citing delays bringing data center capacity online and high
M impact | EQUITY | Nov 15, 2026, 08:02 PM UTC